5.0Top Rating

We’re Funding Sight-Saving Clinical Trials to Treat Childhood Blindness.

Our goal is to advance therapies for pediatric inherited retinal diseases. Our current mission: we are fundraising for a new gene therapy for RP/BBS1 - a rare but devastating cause of childhood blindness.

ENTER A FUNDRAISER
There is hope for childhood blindness
funding the best in retinitis pigmentosa research
impacting clinical trials

Current Giveaways

You can make an impact on saving childhood eyesight by entering our giveaway fundraisers.

See our Feature on Good Morning America!

Luke’s story of seeing the world before losing more vision was featured on GMA, helping propel our mission to the national level.

We were told there was nothing we could do about it. Now, we have every reason to hope, if we stand together.

READ OUR STORY

How We’re Going To Beat Childhood Blindness

What is Retinitis Pigmentosa (RP)?

Retinitis pigmentosa (RP) can be caused by many conditions. Luke’s condition is caused by Bardet-Biedl Syndrome (BBS), which affects multiple organ systems, including the eyes. There is a slow, progressive loss of vision until many BBS patients become blind in their teenage years.

DONATE NOW
We have a chance to change the future for children like Luke.
We were told there was no cure.

Now We're Funding Clinical Trials

The medical research involved in vision saving treatment and restorative therapy is advancing rapidly. This is excellent news! However, funding is significantly limited. Private funding, such as the money we raise, remains the main driver for much of this innovation. Your support is vital to saving children’s vision.

    DONATE NOW

    We Have the Best Helping

    We're supporting sight-saving clinical trials

    WHERE OUR FUNDS GO

    We’ve set up our non-profit to minimize expenses and support sight saving research through philanthropy. Our current target is supporting a therapy for retinitis pigmentosa due to BBS-1. A similar gene therapy, Luxturna, is FDA approved to treat retinitis pigmentosa due to Leber congenital amaurosis. This therapy uses a similar gene therapy model with some minor changes. With each successive gene therapy treatment that is successful, it becomes easier to develop treatments for more genetic subtypes and thus treat a wider patient population.

    Elevating the Rare Disease Community

    OUR PRESENT AND FUTURE

    With your help, we can fight to streamline the FDA approval process for rare diseases, which is incredibly time-consuming and expensive. We want to ensure access to therapies for even the most rare diseases. With each successive new therapy that advances, this opens the door for new therapies. We plan to advocate with regulatory agencies to help enforce the need to continue advancing rare disease approval pathyways.

    partnerships

    How You Can Support

    GENERAL DONATION

    Every donation, no matter how large or small, makes an impact. The efficiency of our mission to support clinical research makes every dollar count.

    DONATE NOW

    GIVEAWAYS

    Enter to win one of our vehicle giveaway fundraisers. Your tax deductible donations give you a chance to win an amazing prize, and support sight-saving research.

    ENTER A GIVEAWAY

    VOLUNTEER

    Create your own events or help out at one of ours! Be a part of our operations, write letters to donors, or help solicit donations: the possibilities are endless.

    CONTACT US
    there is hope

    Meet the Team

    We founded the nonprofit when we found out our son has a rare genetic condition and is slowly going blind. But that really only scratches the surface in terms of our motivation. Since learning of Luke’s diagnosis, we have become strongly connected to the rare-diseases community. While rare diseases are actually not unusual, with more than 7,000 diseases classified by the FDA as rare, each one individually often affects only a small number of people. Thus many rare diseases don’t receive enough attention and resources to help fund research for adequate treatments or even possible cures.